Jennie Zhang

发表

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

G. Garcia-Manero, P. Fenaux, C. Finelli, 2021, Blood.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

M. Cazzola, P. Vyas, G. Mufti, 2020, The New England journal of medicine.

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer

F. Shepherd, P. Ellis, U. Jungnelius, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

E. Neufeld, S. Perrotta, M. Cappellini, 2020, The New England journal of medicine.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

E. Kimby, J. Gribben, F. Bosch, 2012, Leukemia & lymphoma.

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

M. Cazzola, P. Vyas, G. Mufti, 2018, Blood.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

J. Gribben, T. Kipps, M. Hallek, 2016, Leukemia & lymphoma.

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

A. Mead, S. Verstovsek, T. Gerike, 2019, Blood.

Carcinoid tumor causing ileoceccal intussusception in an adult patient

A. Verceles, L. Uradomo, R. Chow, 2019, Journal of community hospital internal medicine perspectives.

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.

R. Foà, A. Chanan-Khan, A. Schuh, 2017, The Lancet. Haematology.

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

E. Kimby, J. Gribben, F. Bosch, 2010 .

Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

R. Foà, A. Chanan-Khan, A. Schuh, 2016 .

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

A. Stamatoullas, G. Garcia-Manero, G. Borthakur, 2018, The Lancet. Haematology.

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

A. Mead, S. Verstovsek, T. Gerike, 2020 .

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

T. Kipps, A. Chanan-Khan, S. Stilgenbauer, 2011 .

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

L. Rassenti, T. Kipps, M. Hallek, 2013 .

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.

P. Greenberg, G. Garcia-Manero, P. Fenaux, 2022, Blood.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

G. Garcia-Manero, S. Paolini, P. Fenaux, 2023, The Lancet.